Regulation of Claudin-1 Expression Via Activation of Ron Tyrosine Kinase and Transforming Growth Factor-Beta Signaling Pathways in Ovarian Carcinoma by Karim, Saya
University of South Florida
Scholar Commons
Outstanding Honors Theses Honors College
12-1-2010
Regulation of Claudin-1 Expression Via Activation
of Ron Tyrosine Kinase and Transforming Growth
Factor-Beta Signaling Pathways in Ovarian
Carcinoma
Saya Karim
University of South Florida
Follow this and additional works at: http://scholarcommons.usf.edu/honors_et
Part of the American Studies Commons
This Thesis is brought to you for free and open access by the Honors College at Scholar Commons. It has been accepted for inclusion in Outstanding
Honors Theses by an authorized administrator of Scholar Commons. For more information, please contact scholarcommons@usf.edu.
Scholar Commons Citation
Karim, Saya, "Regulation of Claudin-1 Expression Via Activation of Ron Tyrosine Kinase and Transforming Growth Factor-Beta
Signaling Pathways in Ovarian Carcinoma" (2010). Outstanding Honors Theses. Paper 40.
http://scholarcommons.usf.edu/honors_et/40
 REGULATION OF CLAUDIN-1 EXPRESSION VIA ACTIVATION 
OF RON TYROSINE KINASE AND TRANSFORMING GROWTH 
FACTOR-BETA SIGNALING PATHWAYS IN OVARIAN 
CARCINOMA 
 
 
By Saya Karim 
 
 
 
A thesis submitted in partial fulfillment of the 
requirements of the Honors College 
 
University of South Florida 
Tampa, FL 
 
 
December 2010  
 
 
Thesis Director: Meera Nanjundan, Ph.D. 
Assistant Professor, College of Arts and Sciences 
 
 
 
 
 
 
 
 
 
 
ii 
 
 
 
Acknowledgments  
 
 
 
First and foremost, I would like to express my sincere and utmost gratitude to my 
Thesis Director, Dr. Meera Nanjundan. Dr. Nanjundan always made time to guide 
me in my project and assist me with my experiments. She was extremely helpful 
and supportive and created a great learning environment for me. I will always so 
thankful to her for the great experience she has given me and for the skills she has 
instilled in me.  
 
I would like to give a special thanks to Christie, who worked with me during 
some of my experiments and was always a pleasure to work with. I would also 
like to thank the past and current members of the lab, especially Dawn, Karthik, 
Kyle, Punashi, Tim, and Anthony for the wonderful atmosphere they helped 
create in lab and for always being a delight to work with.  
 
I am very blessed and grateful for the support that my wonderful family and 
husband have provided for me. Their continuous encouragement has helped me be 
where I am today and I cannot ever thank them enough.  
 
Finally and most importantly, I would like to dedicate this work to my 
grandmother, Golcheen Kader, who has always been an inspiration and a source 
of happiness for me.  
 
 
Thank you, 
Saya Karim 
 
 
 
 
 
 
 
 
iii 
 
Table of Contents 
 
 
Abstract           iv 
 
I. Introduction           1  
 
       A. Background          1   
I. Ovarian Carcinoma        1                                   
II. Dysregulated TGFβ Signaling in Ovarian Cancer    2  
III. Recepteur d’Origine Nantais (RON) Tyrosine Kinase Signaling Pathway 4 
IV. Cross-talk between RON and TGFβ Signaling Pathways to Regulate             
 Claudin-1, a Tight Junction Marker     5 
B. Preliminary Data         7                                   
C. Objectives and Hypotheses        8                                   
 
II. Methods           10  
 
1. Cell Culture          10  
2. Cell Passage          10  
3. Cell Seeding and Treatment with TGFβ and MSP1     10 
4. Cell Seeding and Treatment for siRNA      11 
5. Protein Harvest and Quantification       11 
a. Protein Isolation        11  
b. Bicinchoninic Acid (BCA) Assay for Total Sample Protein Concentration 12 
6. SDS-PAGE Gel (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis) 12 
a. Preparation of SDS-PAGE Gels     12 
b. Running of SDS-PAGE Gels      12 
c. Gel Transfer to Polyvinylidine Fluoride Membrane (PVDF)  
Membranes Using a Semi-Dry Transfer Method   13   
7. Western Blotting         13   
a. Incubation with Antibodies       13 
b. Developing Western Blots       14 
c. Western Blot Membrane Regeneration      14 
8. RNA Isolation          14 
9. Real Time PCR         15   
III. Results           17 
       Part 1: Part 1: RON Knockdown Leads to Upregulated Claudin-1 Protein Levels 17 
       Part 2:  Reduction of Claudin-1 Protein Expression Upon Cellular Treatment with  
                   TGFβ and MSP1         18                                 
       Part 3: SnoN and β-Catenin Knockdown Leads to Upregulated Claudin-1 Protein  
        Levels          22 
       Part 4: RON, SnoN, and β-Catenin Knockdown Leads to Upregulated Claudin-1  
       mRNA Levels         23 
 
IV. Discussion          27 
 
 V. References                  31                            
       
iv 
 
Abstract 
 
 
Epithelial ovarian carcinoma is the most common cause of death among gynecologic 
malignancies in the United States. In the U.S., more than 21,000 women will be diagnosed with 
ovarian cancer and about 15,000 women will die of the disease this year alone. Although 
migration and invasion play key roles in tumor progression, the specific molecular events leading 
to dissemination of ovarian tumor cells have not been well delineated. Tight junctions are an 
integral component of epithelial junction complexes, which play a vital role in maintaining 
epithelial integrity and cell polarity. Disruption of tight junctions is a hallmark of epithelial 
cancer development and malignant progression; specifically decreased claudin-1 expression has 
been associated with progression to tumor malignancy. Herein, we investigate the mechanism by 
which claudin-1 expression is regulated via activation of the TGFβ and RON tyrosine kinase 
receptor signaling pathways. We propose that claudin-1 expression is regulated by the activation 
of the TGFβ signaling pathway (dysregulated in ovarian carcinomas), particularly SnoN/SkiL, a 
key TGFβ co-repressor. In ovarian carcinoma cells, we observed that treatment with TGFβ and 
MSP1 led to a marked reduction in claudin-1 protein expression. Further, we not only noted that 
siRNA targeting RON led to upregulated claudin-1 mRNA and protein expression, but similar 
changes in mRNA and proteins of claudin-1 were observed with SnoN and β-catenin 
knockdown. Strikingly, with β-catenin knockdown, SnoN levels were notably decreased 
suggesting that β-catenin could potentially regulate SnoN expression. Collectively, our results 
demonstrate that claudin-1 expression is regulated by the transcriptional regulators β-catenin and 
SnoN. Since identification of novel biomarkers could be beneficial in diagnosis, prognosis and 
prediction of patient outcomes, these observations regarding the cellular events underlying 
regulation of claudin-1 expression are of translational potential. 
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I. Introduction  
 
A. Background  
 
I. Ovarian Carcinoma 
Epithelial ovarian cancer is the most common cause of death among gynecologic 
malignancies in the United States. Each year in the U.S., more than 21,000 women are diagnosed 
with ovarian cancer and about 15,000 women die of the disease (surveillance, epidemiology, and 
end results (SEER) Program of the National Cancer Institute). Early stage of the disease is 
associated with minimal or an absence of symptoms. Hence, most cases are diagnosed at an 
advanced stage when the disease has aggressively disseminated the cells from the primary tumor. 
Unfortunately, this results in poor prognosis for these patients.  
The specific 
molecular events 
leading to 
metastases of 
ovarian tumor cells 
have not been well 
studied, but it is 
known that 
migration and 
invasion play a key 
role in the 
progression.  These processes are carried out through epithelial–mesenchymal transition (EMT) 
which changes the morphology of the rigid, cuboidal epithelia to a mesenchymal form. EMT is 
Epithelial-Mesenchymal Transition (EMT) 
 
Figure 1.1-Two mechanisms through which EMT occurs in ovarian cells are shown. Cells  
undergoing  EMT experience an altered morphology of the rigid, cuboidal epithelia to a more 
fibroblast-like mesenchymal phenotype.
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initiated through the dissolution of cell–cell junctions, adherens, tight and desmosomal junctions 
between adjacent epithelial cells[1]. This is followed by cytoskeleton reorganization, degradation 
of basement membranes and stroma, and enhanced growth rate[1]. Dissolution of the cell 
junctions may occur either as a result of the acquisition of genetic and epigenetic changes that 
result in mutations of their components or through repression of their expression at the 
transcriptional level [2].  
 
II. Dysregulated TGFβ Signaling in Ovarian Cancer 
 
Transforming growth factor-beta (TGFβ) is a multifunctional regulatory polypeptide that 
controls many aspects of cellular function such as cell proliferation, differentiation, migration, 
apoptosis, adhesion, angiogenesis, immune surveillance, and survival[3]. The actions of TGFβ 
are dependent on several factors such as cell type, growth conditions, and the presence of other 
polypeptide growth factors. TGFβ has dual functionality: (1) as a tumor suppressor (through its 
effects on proliferation and apoptosis) and (2) as a tumor promoter (through effects on migration, 
invasion, angiogenesis and the immune system)[3]. During the early stages of epithelial 
tumorigenesis, TGFβ inhibits tumor development and growth by inducing cell cycle arrest and 
apoptosis. In late stages of tumor progression, tumor cells become resistant to growth inhibition 
due to inactivation of the TGFβ signaling pathway or aberrant regulation of the cell cycle[3].  
The effects of TGFβ are exerted through TGFβ type 1 (TGFβRI) and type 2 receptors 
(TGFβRII)[3]. Binding of the ligand causes the formation of heterotetrameric active receptor 
complexes that result in the phosphorylation of the type 1 receptor by the type 2 receptor [3]. The 
functional receptor complex regulates the activation of downstream Smad-dependent and Smad-
independent pathways[3]. In the Smad-dependent signaling pathway, TGFβ binds TGFβRII 
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which activates TGFβRI[3]. The activated TGFβRI then recruits and phosphorylates receptor-
regulated Smads (R-Smads), notably Smad2/3, which then form a complex with the Co-Smad, 
Smad4[3]. This complex then translocates to the nucleus to regulate transcription of TGFβ target 
genes such as cyclin-dependent kinase inhibitors (i.e. p21, involved in regulating cell 
survival)[3]. Thus, the overall effect of the Smad-dependent signaling is to inhibit cell growth. 
Interestingly, a mutation in 
Smad4 leads to the loss of the 
tumor suppressor function of 
TGFβ[3].  
To date, several genes 
that antagonize the inhibitory 
effect of TGFβ in ovarian 
cancer have been identified 
(i.e. EVI1[4], SnoN/SkiL[5], 
AML1/RUNX1[6], PKCι[7]). 
Among these TGFβ 
antagonists, SnoN (which is a 
member of the SKI family of 
nuclear proto-oncogenes) has 
been well characterized[8]. In 
the nucleus, SnoN can elicit 
either pro-oncogenic or anti-
oncogenic activities via the following two pathways: (1) SnoN may promote epithelial cell 
Smad-Dependent TGFβ Signaling
 
Figure 1.2- The Smad-dependent TGFβ signaling pathway demonstrating the role of 
the  transcriptional co-repressor SnoN in the nucleus.
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proliferation by antagonizing the growth-inhibitory activity of the TGFβ/Smad pathway, or (2) 
very high levels of SnoN may trigger premature senescence via stabilization of p53 in a PML-
dependent manner, respectively[8]. For this reason, SnoN has been associated with these pro- 
and anti-oncogenic activities linked to cancer progression.  
 
III. Recepteur d’Origine Nantais (RON) Tyrosine Kinase Signaling Pathway 
 
 Another signaling 
pathway that is associated 
with invasive cancers is that 
activated by Recepteur 
d’Origine Nantais (RON), a 
receptor tyrosine kinase 
which is a member of the 
MET proto-oncogene 
family[9]. Mature RON is a 
180-kDa heterodimer 
composed of a 40-kDa α-
chain and a 150-kDa 
transmembrane β-chain with 
intrinsic tyrosine kinase 
activity[9]. The ligand for 
RON is the macrophage-
stimulating protein (MSP1)[9]. MSP1 is 725 amino acids in length and is released by 
RON Tyrosine Kinase Signaling Pathway 
 
Figure 1.3- The RON tyrosine kinase signaling pathway.  When activated, GSK-3 
(glycogen synthase kinase-3) phosphorylates β-Catenin, targeting it for degradation in  
the proteasome. 
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hepatocytes into the blood, where it is later proteolytically modified to a form that can bind to 
RON leading to activation of its tyrosine kinase activity[9]. Activation of RON by MSP1 
stimulates multiple signaling pathways including PI-3 kinase, Ras, MAP kinase, DVL, GSK-3β, 
Smad and β-catenin leading to induction of cell adhesion, dissociation, migration and matrix 
invasion[10]. 
 
IV. Cross-talk between RON and TGFβ Signaling Pathways to Regulate Claudin-1, a Tight 
Junction Marker 
 
Tight junctions are an integral part of epithelial junction complexes and play a vital role 
in creating and maintaining epithelial integrity and cell polarity[11]. Structurally, tight junctions 
are composed of proteins and lipids surrounding the lateral membrane of epithelial cells[12]. A 
group of integral membrane proteins known as claudins create the backbone of tight junctions. 
At present, more than 20 claudin genes have been identified[11]. Disruption of tight junctions is 
a hallmark of epithelial cancer development and progression towards malignancy[13]. Altered 
expression of claudins such as loss of claudin-1 expression has been shown to correlate with 
increased invasiveness and malignant progression of certain epithelial cancers[14, 15].  
Various mechanisms have been implicated in regulation of claudin-1 expression. In colon 
cancers, Smad4 of the TGFβ pathway has been shown to repress claudin-1 transcription through 
modulation of β-catenin/T-cell factor/ lymphocyte enhancer factor activities[16]. Hence, there is 
an inverse relationship between the expression of claudin-1, a metastasis-promoting protein, and 
Smad4, a tumor suppressor protein, in colon cancer cell lines. With respect to the RON pathway, 
studies with Madin-Darby Canine Kidney (MDCK) cells have shown that activation of RON 
decreases E-cadherin and claudin-1 expression. Additionally, Snail and Slug, of the Snail family 
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of transcription factors, have been implicated as transcriptional repressors of claudin-1 in MDCK 
cells[17]. It has further been indicated that activation of Erk1/2 signaling cascades is the first step 
required for RON to exert the inhibitory effect on claudin-1 expression[17]. Ligand-dependent 
RON activation disrupts tight junctions and impairs their functions via diminished claudin-1 
expression[17]. Hence, activation of RON has a fundamental impact on integrity and function of 
epithelial cell–cell junctions. Alterations of these cellular structures are vital in RON-mediated 
tumorigenic activities leading to malignant progression. 
Previous studies have shown increased expression of RON tyrosine kinase in pancreatic 
tissues with Smad4 deletions in comparison to normal Smad4 expressing pancreatic cancer 
specimens[18]. This indicates that the Smad-dependent TGFβ signaling pathway is critically 
involved in transcriptional regulation of RON tyrosine kinase. Further studies have shown that 
that RON and TGFβ can interact collaboratively including induction of EMT[13]. Recent studies 
have also shown that TGFβ transcriptional mediators, EVI1 and RUNX1[4, 6], are associated 
with Smad and act as transcriptional co-repressors of RON tyrosine kinase [Shafiq and 
Nanjundan, unpublished results].  
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B. Preliminary Data 
 
The cell line highlighted in red, BxPC-3, are Pancreatic Adenocarcinoma cells.  In 
response to MSP1, activation of the RON tyrosine kinase has been reported. The protein 
expression profiling results show that expression of RON, β-Catenin, and claudin-1 are 
correlated 
positively in 
BxPC-3 cells. The 
cell line 
highlighted in 
blue, SKOV3, are 
ovarian cancer 
cells that can be 
activated by the 
MSP1 receptor. 
The protein 
expression 
profiling results show that RON, claudin-1 and Smad2/3 expression are highly correlated with 
SKOV3 cells. The cell line highlighted in green, HEY, are human ovarian carcinoma cells.  The 
protein expression profiling results show that expression of β-catenin, claudin-1 and Smad2/3 are 
positively correlated in HEY cells. The cell line highlighted in yellow, H358, are squamous lung 
carcinoma cells that can be activated by the MSP1 receptor. The protein expression profiling 
Cell Line Profile 
 
Figure 1.4- Cell line profile produced by Western analysis showing protein expression levels of various 
proteins. Study primarily focused on the cell lines highlighted in the figure.  
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results show that expression of RON, β-catenin, and Smad2/3 are positively correlated in H358 
cells. 
C. Objectives and Hypotheses  
 
Tight junctions are an integral component of epithelial junction complexes and play a 
vital role in creating and maintaining epithelial integrity and cell polarity. Disruption of tight 
junctions is a hallmark of epithelial cancer development and malignant progression. The loss of 
claudin-1 expression has been shown to be correlated with increased invasiveness and malignant 
progression of certain epithelial cancers[14, 15]. Various mechanisms have been implicated in 
regulation of claudin-1 expression including regulators of the TGFβ and RON Tyrosine Kinase 
pathways. As stated in the Background, studies with colon cancers have shown that Smad4, a co-
Smad involved in the TGFβ pathway, represses claudin-1 expression. Furthermore, studies in 
breast cancer and MDCK cells show that RON activation disrupts tight junctions and impairs 
their functions through diminished claudin-1 expression[17]. Hence, activation of RON has a 
fundamental impact on integrity and function of epithelial cell–cell junctions and alterations of 
these cellular structures are vital components in RON-mediated tumorigenic activities that assist 
malignant progression.  
Undeniably, other mechanisms play a role in regulation of claudin-1 expression in cancer 
cell migration and invasion. Thus, we hypothesize that claudin-1 expression is regulated by the 
activation of the transforming growth factor beta signaling pathway, particularly through 
SnoN/SkiL, a key TGFβ co-repressor[5]. Scientific evidence suggests that there is cross-talk 
between the TGFβ pathway and receptor tyrosine kinases such as RON which is aberrantly 
expressed in invasive carcinomas[9, 11]. The goal of the proposed studies is to delineate the 
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signaling pathways that are involved in regulating the expression of this tight junction protein 
whose expression is dysregulated. Thus, the specific aims are as follows:   
 
Specific Aim #1: We will test the hypothesis that altered expression of RON tyrosine kinase 
leads to dysregulated claudin-1 expression  
Our goal is to determine whether knockdown of RON using siRNA (targeting wild type 
Ron Tyrosine Kinase) leads to altered claudin-1 expression via up/downregulated expression of 
TGFβ signaling mediators including Smad2/3, SnoN, and β-catenin. 
Specific Aim #2: We will test the hypothesis that cellular treatment with TGFβ and MSP1 leads 
to altered expression levels of Claudin-1  
Our goal is to investigate the changes in claudin-1 expression via cellular activation with 
TGFβ and MSP1 ligands which activate the TGFβ receptor and RON tyrosine kinase receptor, 
respectively.  
Specific Aim #3: We will test the hypothesis that knockdown of β-catenin and SnoN upregulates 
claudin-1 expression  
Our goal is to investigate the claudin-1 expression following cellular treatment with 
siRNA targeting β-catenin and SnoN in ovarian carcinoma cells.  
 
The disruption of tight junctions is a hallmark of epithelial cancer development and 
malignant progression wherein decreased claudin-1 expression is involved in this progression to 
malignancy. Since identification of novel biomarkers could be beneficial in diagnosis, prognosis 
and prediction of patient outcomes, it is of great importance to elucidate the detailed cellular 
events underlying claudin-1 expression. 
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II. General Methods 
  
  
1. Cell Culture  
 
H358 Bronchial Alveolar Carcinoma and BxPC-3 Pancreatic Adenocarcinoma 
cell lines were obtained from ATCC while the HEY Ovarian Carcinoma and SKOV3 
Ovarian Carcinoma cell lines were kindly provided by Dr. Mills (MD Anderson Cancer 
Center, Houston Texas). All four cells lines were maintained in RPMI 1640 containing 8% 
Fetal Bovine Serum and 1% penicillin-streptomycin in a 5% CO2 humidified incubator at 
37°C. 
2. Cell Passage  
For experiments, cells were utilized at passage numbers below 30. Cells 
maintained in flasks were removed from the CO2 incubator. Media was first removed from 
the flasks followed by the addition of trypsin. To aid cell detachment, the flasks were gently 
tapped followed by the addition of complete media. The cell-media solution was then 
collected into aliquot tubes and centrifuged at 1,000rpm for 5 minutes which resulted in a 
pellet fraction that was retained while the supernatant was discarded. The pellet was 
resuspended in an appropriate volume of complete media and 1/5th was then plated into new 
flasks. 
3. Cell Seeding and treatment with TGFβ and MSP1 
 
H358, BxPC-3, SKOV3 and HEY cells were seeded at 250,000 cells per well in 
6-well plates. Twenty-four hours post seeding, cells were treated with TGFβ (50pM), MSP1 
(10ng/mL), and a combination of these two ligands (50pM TGFβ and 10ng/mL MSP1), 
across the following time courses: a) 1 minute, 5 minutes, 1 hour, 3 hours and 6 hours (short 
11 
 
time course) and b) 24 hours, 48 hours, 72 hours and 96 hours (long term time course). 
Immediately upon completion of these treatments, samples were placed on ice to terminate 
cellular activities.  
4. Cell Seeding and treatment for siRNA 
H358, BxPC-3, SKOV3 and HEY cells were seeded at 250,000 cells per well in 
6-well plates. Twenty-four hours post seeding, cells were treated either with non-targeting 
siRNA (control) or RON siRNA (1X). The following day, the cells were allowed to recover 
followed by another siRNA transfection (2X) to obtain a greater reduction in RON 
knockdown. The following day, cells were allowed to recover followed by cellular treatment 
for 24 hours with TGFβ (50pM), and MSP1 (10ng/mL). Immediately upon completion of 
these treatments, samples were placed on ice to terminate cellular activities.  
Additional experimentations included siRNA treatment of SKOV3 and HEY cells 
with β-catenin siRNA and SnoN siRNA. Cells were similarly seeded at 250,000 cells per 
well in 6-well plates and siRNA methodology was followed as described above.   
5. Protein Harvest and Quantification 
 
a. Protein Isolation 
 
Media was removed from each well of 6-well plates followed by the addition of 
1X Phosphate Buffer Saline (PBS). The plates were gently rocked for a few seconds and the 
PBS was removed from each well. One-hundred µL of RPPA Lysis Buffer (containing a 
cocktail of protease inhibitors) was added to each well and the plates were incubated on ice 
for one hour. After incubation, the cells were scraped vigorously and the resulting lysate 
collected into Eppendorf tubes. The samples were then centrifuged at 15,000rpm for 10 
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minutes as 4°C. Following centrifugation, the pellet was discarded while the supernatant 
was retained for further analysis. Samples were kept on ice at all times to minimize protein 
degradation. 
b. Bicinchoninic Acid (BCA) Assay for Total Sample Protein Concentration 
 
   Bovine Serum Albumin (BSA) standards (0, 25, 50, 100, 250, 500, 750, 1000, 
2000µg/mL) and samples were pipetted in duplicate into a 96-well plate (2µL per well). 
Next, BCA Reagent A and BCA Reagent B were mixed at a ratio of 9.8ml:0.2ml. Two-
hundred µL of the BCA Reagent mixture was added to each well containing a standard or 
sample. The plate was then placed in a 37°C incubator for 30 minutes. After incubation, the 
plate was read at 570nm in a BioTek Synergy 2 plate reader. The resulting data was 
analyzed using a Microsoft Office Excel document to generate a standard curve and 
determine the protein concentrations of the unknown samples. These samples were then 
diluted to 1-2mg/mL with lysis buffer and 6X SDS sample loading buffer to prepare gel 
loading sample to run of SDS-PAGE gels. 
6. SDS-PAGE Gel (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis)  
 
a. Preparation of SDS-PAGE Gels 
 
Components for preparation of lower and upper gel were mixed in two separate 
50ml aliquot tubes. The quantity used of each component (NANOpure water, gel buffer 
(upper or lower), 30% acrylamide, APS and TEMED) was determined by the percentage of 
the gel required (i.e. 8% or 12%). The lower gel mixture was first poured into a Criterion gel 
cassette. After lower gel polymerization, the upper gel was mixed, poured, and a comb was 
inserted for formation of loading wells (18 wells). 
b. Running of SDS-PAGE Gels 
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Samples were boiled at 95°C for 5 minutes, vortexed for 2 seconds, and 
centrifuged for 10 seconds at 15,000 rpm. The gels were placed appropriately into the 
Criterion electrophoresis system. The basin of the gel cassette and the external chambers of 
the gel apparatus were filled with Running Buffer. 20µl of samples and molecular weight 
markers were loaded into the appropriate wells. The gels were electrophoresed for 2 hours at 
100 volts. 
c. Gel Transfer to Polyvinylidine Fluoride Membrane (PVDF) Membranes Using a 
Semi-Dry Transfer Method 
Prior to the western blotting process, the gels were transferred to a high protein 
binding membrane (PVDF). For transfer, the gel was removed from the cassette and 
incubated briefly with transfer buffer. The membrane was activated by soaking for one 
minute in 100% methanol followed by rinsing 3 times with NANOpure water, and 
immersion in Transfer Buffer. Blotting paper was soaked in Transfer Buffer and placed on 
the blotting panel of the Trans-Blot apparatus. The PVDF membrane, the gel, and another 
piece of blotting paper were then placed on top of this blotting paper (in this order). 
Throughout this process, care was taken to remove all bubbles from this “blot sandwich”. 
The Trans-Blot apparatus was closed and the transfer was conducted for 2 hours with a 
voltage limit of 20 Volts. Depending on the number of blots transferred, a constant current 
of 0.11 amps (1 blot) or 0.15 amps (2 blots) was utilized. 
7. Western Blotting 
 
a. Incubation with Antibodies 
 
After the gels were transferred to membranes, the membranes were washed in 1X 
Tris-Buffered Saline Tween-20 (TBST) for 10 minutes on a platform rotator. Then, the 
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TBST was drained and the membrane was placed on the platform rotator for 1 hour in 1X 
TBST with 5% milk for “blocking”. The milk solution was then removed and the membrane 
was incubated with appropriate primary antibody on the rotator overnight at 4°C. The 
membrane was washed in 1X TBST for 1 hour on the rotator with the TBST being replaced 
every 15 minutes. Appropriate secondary antibody was then applied to the membrane and 
incubated with shaking at room temperature for 1 hour. The membrane was then washed in 
1X TBST for 1.5 hours on the rotator with the TBST being replaced every 15 minutes.  
b. Developing Western Blots 
 
To develop western blots, the developer was turned on and warmed up at least 20 
minutes in advance. Prior to use, the ECL developing reagents (HRP Luminol and Peroxide 
Buffer) were mixed at a 1:1 ratio. After secondary antibody incubation and subsequent 1X 
TBST washes, the membranes were completely covered with the ECL mixture and 
incubated at room temperature for 5 minutes. The blots were then placed in the developing 
cassette and moved to the darkroom where Kodak film was exposed to the blot and 
developed.  
c. Western Blot Membrane Regeneration 
 
Blots were regenerated after developing by washing in 1X TBST for 10 minutes 
on the platform rotator. TBST was then discarded and 20 mL of restoration buffer (Pierce) 
was applied to the membrane. The membrane was incubated for 1 hour at 50°C with 
moderate shaking, then washed in 1X TBST for 10 minutes on the platform rotator, and then 
blocked for 2 hours in 1X TBST containing 5% milk. The milk solution was discarded and 
the membrane was incubated with primary antibody on the rotator overnight at 4°C. 
8. RNA Isolation  
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RNA isolation was performed using the QIAGEN RNeasy Mini Kit. Forty-eight 
hours post 2X siRNA transfection, cells were washed with 1ml of Dulbecco's Phosphate 
Buffered Saline (DPBS). After discarding the DPBS, 350µl of RLT buffer was added to 
each well. Following one minute incubation, the wells were scraped and lysates transferred 
into shredder columns for homogenization. 
The columns were centrifuged for 2 minutes at 14,000 rpm. 300µl of 70% ethanol 
(RNA grade) was added to the eluate. After mixing, eluates were transferred into spin 
columns and centrifuged for 15 seconds at 10,000 rpm. Then, the flow-through was 
discarded, 700µl of RW1 buffer was added to each spin column, and centrifuged for 15 
seconds at 10,000 rpm. After the flow-through was discarded again, 500µl of RPE buffer 
was added to each spin column, and centrifuged for 15 seconds at 10,000 rpm. Next, the 
flow-through was discarded, another 500µl of RPE buffer was added to each spin column, 
and centrifuged for 2 minutes at 10,000 rpm. The spin columns were then centrifuged for 1 
minute at 14,000 rpm followed by the addition of 30µl of RNase free water. This was 
followed by one minute incubation and centrifugation for one minute at 10,000 rpm. The 
flow-through was re-added to the spin columns followed by the addition of a further 10µl of 
RNase free water and then centrifuged for one minute at 10,000 rpm. The spin columns 
were then discarded and the RNA samples were transferred into appropriately labeled 
Eppendorf tubes. The RNA concentration of each sample was quantified using the 
NANOdrop apparatus and 20ng/µl dilutions (with total volumes of 50µl) were prepared. All 
RNA samples were stored at -80°C until further use. 
9. Real Time PCR 
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Real Time PCR was used to quantify the mRNA transcript levels of claudin-1 
following SnoN, β-catenin, and RON knockdown using siRNA in HEY cells. β-Actin 
probe/primers were used to determine the β-Actin RNA levels as an endogenous control. 
For both the β-Actin control and genes of interest, master mixes were prepared using the 
components provided in the Applied Biosystems OneStep RT-PCR Kit.  
The master mixes were pipetted into a 96-well plate followed by the addition of 
40ng of RNA.  All samples were analyzed in duplicate. PCR was run using the StepOnePlus 
Real-Time PCR System which was programmed as follows: (1) 48°C for 30 minutes 
(reverse transcriptase reaction), (2) 95°C stage for 10 minutes, and (3) 40 cycles alternating 
between 95°Cfor 15 seconds and 60°C for 1 minute. Results were analyzed using the 
following formula: 2-ΔΔCT.   ΔCT= CT value of gene of interest minus CT value of β-Actin. 
ΔΔCT= ΔCT minus ΔCT of CT of siRNA sample.  
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III. Results  
Part 1: RON Knockdown 
Leads to Upregulated Claudin-
1 Protein Levels 
 In Aim #1, we tested the 
hypothesis that dysregulated 
RON tyrosine kinase expression 
leads to altered claudin-1 protein 
levels. In high RON Tyrosine 
Kinase expressing BxPC-3, H358 
and SKOV3 cell lines, the effects 
of RON knockdown using siRNA 
were investigated 
(results shown in Figure 
3.1). Western blotting 
was performed to 
examine the expression 
of TGFβ signaling 
mediators (Smad2/3 and 
SnoN) as well as β-
Catenin. RON 
knockdown led to 
greater than 80% reduction in RON protein expression in all three cell lines. Coincident with 
    
 
Figure 3.1- Western analysis of RON knockdown in SKOV3, H358, and BxPC-3 
cells. Cells were seeded at 250,000 cells per well in 6-well plates. Twenty-four 
hours post seeding, cells were treated either with non-targeting siRNA (control) 
or RON siRNA (1X). The following day, the cells were allowed to recover followed 
by another siRNA transfection (2X). Protein was harvested, quantified, and run 
on SDS-PAGE.  Following the transfer of gels to PVDF membranes, Western 
blotting was performed using antibodies targeting (1) RON, (2) SnoN, (3) claudin-
1, (4) β-catenin, (5) Smad2/3, and (6) GAPDH used as the loading control. 
 
Figure 3.2- Western analysis of RON knockdown in HEY cells. Cells were seeded at 250,000 
cells per well and at 24 hours post seeding, were either treated with non-targeting siRNA 
(control) or RON siRNA (1X). Another siRNA transfection (2X) was performed the following 
day to obtain a greater reduction in RON knockdown. Protein was then harvested, quantified, 
run on SDS-PAGE, and transferred to PVDF membranes. Western blotting was performed 
using antibodies targeting (1) RON, (2) SnoN, (3) claudin-1, (4) β-catenin, (5) Smad2/3, and 
(6) GAPDH used as a loading control. 
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decreased Ron levels, we observed that, (1) claudin-1 protein levels were increased in both 
SKOV3 and H358 cell lines, (2) β-catenin protein levels were increased in SKOV3 cells slight 
increase in SnoN expression in SKOV3 cells.  
To further validate these changes in an independent cell line, we selected HEY cells, a 
highly metastatic ovarian cancer cell line (see Figure 3.2). Similar to SKOV3 and H358 cells 
(Figure 3.1), we observed that claudin-1 protein levels were increased with RON knockdown in 
HEY cells. Furthermore, similar to SKOV3 cells (Figure 3.1), β-catenin protein levels were 
increased with RON knockdown in HEY cells. However, SnoN expression levels appear to be 
unchanged in HEY cells in contrast to SKOV3 cells.   
 
Part 2:  Reduction of Claudin-1 Protein Expression Upon Cellular Treatment with TGFβ 
and MSP1 
 The goal of Aim #2 was to investigate changes in claudin-1 protein expression following 
cellular activation with TGFβ and MSP1 ligands which activate the TGFβ receptor and RON 
tyrosine kinase receptor, respectively. The effects of MSP1 and TGFβ activation on claudin-1 
 
Figure 3.3-Effects of MSP1 and TGFβ on ERK activation (pERK1/2) in H358, BxPC-3, and SKOV3 cells. Cells 
were seeded at 250,000 cells per well and twenty-four hours post seeding, cells were treated with TGFβ (50pM) 
and MSP1 (10ng/mL) across the following time course: 1 minute, 5 minutes, 1 hour, 3 hours and 6 hours (short 
time course). Western blotting was performed using antibodies targeting (1) pERK1/2 and (6) GAPDH used as a 
loading control. 
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expression were investigated across a series of short (up to 6 hours) and long (up to 96 hours) 
time course treatments. In the short-term time course, Western blotting was performed to 
examine the activation of pERK1/2 (also known as MAPK), as shown in Figure 3.3. We 
observed a marked activation of MAP kinase at 3 hours post treatment in BxPC-3 cells, 1 hour 
post treatment in H358 cells and 5 minutes post treatment in SKOV3 cells. This was detected 
using an antibody against MAP kinase which specifically detects its phosphorylation status.  
In the long-term time course, expression levels of claudin-1, β-catenin, Smad2/3, and 
SnoN were investigated up to 96 hours post MSP1 and TGFβ addition. As shown in Figure 3.4, 
we observed decreased claudin-1 expression 24 hour post treatment with MSP1 and TGFβ in 
both BxPC-3 and H358 cells. Furthermore, we observed decreased claudin-1 expression 24 to 96 
hours post TGFβ treatment in SKOV3 cells. β-catenin protein levels were increased 24 hours 
post treatment with both MSP1 and TGFβ in SKOV3 cells. SnoN expression levels were 
increased 24 hours post treatment with combinatorial treatment of both MSP1 and TGFβ in 
SKOV3 cells. In contrast, we did not detect any marked changes in Smad2/3 expression.  
 
Figure 3.4- Effects of long term cellular treatments with MSP1 and TGFβ treatment H358, BxPC-3, and SKOV3 cells. 
Cells were seeded at 250,000 cells per well in 6-well plates. Twenty-four hours post seeding, cells were treated with TGFβ 
(50pM), MSP1 (10ng/mL), across the following time course: 24 hours, 48 hours, 72 hours, and 96 hours. Protein was 
harvested, quantified, separated by SDS-PAGE, and transferred to PVDF membranes. Western blotting was then 
performed using antibodies targeting (1) claudin-1, (2) β-catenin, (3) Smad2/3, (4) SnoN, and (4)  GAPDH used as the 
loading control. 
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Figure 3.5 shows the 
western analysis of short and 
long-term time courses of 
combinatorial treatments of 
both MSP1 and TGFβ. Since 
the main focus of this study is 
ovarian carcinomas, we 
selected SKOV3 cells to 
examine the effects of 
combinatorial treatments of 
these two ligands at 24 hours post-
treatment. MAP kinase activation 
(via detection of phosphorylated 
ERK1/2) is observed in short time 
course TGFβ treatment but not in 
combination treatment with both 
MSP1 and TGFβ. In the long time 
course, activation of MAP kinase 
decreased with both MSP1 and 
TGFβ but more dramatically upon 
combination of both of these two 
ligands. Consistent with our previous observations, claudin-1 expression levels decreased with 
only MSP1 or TGFβ alone; however, the reduction in claudin-1 was more marked when cells 
Figure 3.5- Combinatorial short and long-time course cellular treatment with MSP1 
and TGFβ in SKOV3 cells. Cells were seeded at 250,000 cells per well and twenty-four 
hours post seeding, cells were treated with TGFβ (50pM) and MSP-1 (10ng/mL), or a 
combination of these two ligands (50pM TGFβ with 10ng/mL MSP1) either at 5 
minutes (short time course, STC) or at 24 hours (long time course, LTC). Cell lysates 
were harvested, protein quantified, separated by SDS-PAGE, and transferred to PVDF 
membrane. Western blotting was using antibodies detecting (1) pERK1/2, (2) β-catenin, 
(3) claudin-1, and (4) GAPDH as the loading control. 
Figure 3.6- Long time course treatment of MSP1 and TGFβ in HEY cells. Cells 
were seeded at 250,000 cells per well and twenty-four hours post seeding, cells 
were treated with TGFβ (50pM), and MSP-1 (10ng/mL), across the following 
time course: 24 hours, 48 hours, 72 hours and 96 hours. Protein was then 
harvested, quantified, separated by SDS-PAGE, and transferred to PVDF 
membranes. Western blotting was performed using antibodies detecting (1) β-
catenin, (2) claudin-1, (3) Smad2/3, (4) SnoN, and (5) GAPDH as a loading 
control. 
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were treated with both TGFβ and MSP1. In contrast to these dramatic changes in claudin-1 
protein levels, β-catenin expression levels were unchanged.  
To further validate these observations and determine whether these results can be 
generalizable to other carcinoma cell lines, we repeated these studies using HEY cells. Figure 3.6 
displays the Western analysis of the long time course while Figure 3.7 displays the Western 
analysis of the combination treatments of MSP1 and TGFβ for two selected time points (i.e. 24 
and 48 hours). In the long term time course in HEY cells (Figure 3.6), claudin-1 expression 
levels decreased 24 hours post treatment with MSP1 and TGFβ.  Smad2/3 expression levels 
decreased 48 hours post treatment with TGFβ while no changes were seen in SnoN or β-catenin 
expression levels. In the combination study 
(shown in Figure 3.7), we observed a marked 
reduction in claudin-1 expression following 
24 hours post treatment with MSP1, TGFβ, 
and the combination of these two ligands. In 
contrast, the protein expression levels of 
Smad2/3 were increased 24 hours post 
treatment with MSP1, TGFβ, and the 
combination of these two ligands. SnoN 
expression levels were slightly increased post 
24 and 48 hours treatment of MSP1, TGFβ, 
with a more marked increase with the 
combinatorial treatment at 48 hours post treatment. Similarly, β-catenin protein expression levels 
were increased at 24 and 48 hour post treatment with TGFβ.  
Figure 3.7- Long time course treatment of MSP1, TGFβ and the 
combination of the two ligands in HEY cells.  Cells were seeded 
at 250,000 cells per well and twenty-four hours post seeding, 
cells were treated with TGFβ (50pM) and MSP-1 (10ng/mL), 
and a combination of these two ligands (50pM TGFβ and 
10ng/mL MSP-1) at 24 and 48 hours. This was followed by 
protein harvesting, quantification, separation by SDS-PAGE, 
and transferred to PVDF membranes. Western blotting was 
performed using antibodies detecting (1) SnoN, (2) claudin-1, (3) 
β-catenin,(4) Smad2/3, and (5) GAPDH as a loading control. 
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Part 3: SnoN and β-Catenin Knockdown Leads to Upregulated Claudin-1 Protein Levels 
Aim #3 of this study was to test the hypothesis that knockdown of β-catenin and SnoN 
upregulates claudin-1 
expression. Initially, 
SKOV3 cells were used 
to investigate the 
claudin-1 expression 
following cellular 
treatment with siRNA 
targeting β-catenin. 
However, SKOV3 cells 
(as shown in Figure 3.8) 
were extremely slow 
growing and thus, the 
protein amounts were 
suboptimal for further 
analyses. Hence, HEY 
cells were used since 
they yielded an 
abundance of protein for 
Western analyses. 
Additional studies included siRNA treatment of HEY cells with β-catenin siRNA and SnoN 
siRNA, as noted in Figure 3.9. With β-catenin siRNA, the combination treatment of MSP1 and 
Figure 3.8- Effects of β-catenin knockdown in SKOV3 cells. Cells were seeded at 250,000 cells 
per well in 6-well plates. Twenty-four hours post seeding, cells were treated either with non-
targeting siRNA (control) or β-catenin siRNA (1X). The following day, the cells were allowed to 
recover followed by another siRNA transfection (2X). Protein was harvested, quantified with 
BCA, and run on SDS-PAGE.  Following the transfer of gels to PVDF membranes, Western 
blotting was performed using antibodies detecting (1) β-catenin, (2) SnoN, (3) claudin-1, and (4) 
GAPDH as a loading control. 
 
Figure 3.9- Effects of β-catenin knockdown in HEY cells.  Cells were seeded at 250,000 cells  
per well in 6-well plates. Twenty-four hours post seeding, cells were treated either with non-
targeting siRNA (control) or SnoN siRNA (1X), or β-catenin siRNA (1X). The following day, 
the cells were allowed to recover followed by another siRNA transfection (2X). The following 
day, cells were allowed to recover followed by cellular treatment for 24 hours with TGFβ 
(50pM), MSP1 (10ng/mL), and a combination of the two ligands (50pM TGFβ and 10ng/mL 
MSP1). Protein was harvested, quantified, and run on SDS-PAGE.  Following the transfer of 
gels to PVDF membranes, Western blotting was performed using antibodies detecting (1) 
SnoN, (2) β-catenin, (3) claudin-1, (4) Smad2/3, and (5) GAPDH as a loading control. 
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TGFβ led to increased claudin-1 expression compared to β-catenin siRNA cells treated with only 
MSP1 or TGFβ. SnoN expression decreased in cells treated with β-catenin siRNA. Smad2/3 
expression is decreased with MSP1, with a further marked decrease upon TGFβ treatment as 
well as with the combination of MSP1 and TGFβ. An even more dramatic reduction in protein 
levels was observed with Smad3 in contrast to Smad2.  
 
Part 4: RON, SnoN, and β-Catenin Knockdown Leads to Upregulated Claudin-1 mRNA 
Levels 
To validate the 
results we obtained in the 
above sections where we 
examined protein levels, 
we performed RNA 
analysis to determine 
whether these changes occurred at the 
transcriptional level. HEY cells were 
transfected with control, SnoN, β-catenin, and 
RON siRNA. RNA was then isolated and 
quantified (A260/A280=2.0). The RNA 
concentrations for these samples are presented 
in Table 3.1. The RNA concentrations for all 
samples were standardized to 20ng/μl and 
   
Figure 3.10 – PCR Amplification Plot of RNA levels of SnoN, 
claudin-1, and RON in siRNA treated HEY cells.  
Table 3.1- RNA concentrations and purity of samples. 
Sample ID ng/µl λ260 λ280 260/ 280 
Control siRNA-1 855.03 21.376 10.372 2.06 
Control siRNA-2 966.05 24.151 11.73 2.06 
RON siRNA-1 1061.38 26.535 12.854 2.06 
RON siRNA-2 1063.95 26.599 12.885 2.06 
SnoN siRNA-1 842.19 21.055 10.18 2.07 
SnoN siRNA-2 661.59 16.54 8.024 2.06 
β-Catenin siRNA-1 1187.45 29.686 14.429 2.06 
β-Catenin siRNA-2 715.44 17.886 8.71 2.05 
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qPCR (quantitative PCR) was then performed using probes specific to claudin-1, SnoN, and 
RON mRNA transcripts.    β-Actin probes/primers were used as an endogenous control. 
      Table 3.3 – Raw Data and Calculation of CT values from qPCR. 
Probe Sample CT ΔCT ΔΔCT 2^-ΔΔCT 
Claudin-1 Control 
siRNA-1 
32.72 9.48 0 1 
 Claudin-1 Control 
siRNA-2 
32.87 9.58 0.096 0.935 
Claudin-1 SnoN 
siRNA-1 
31.99 9.22 -0.266 1.203 
Claudin-1 SnoN 
siRNA-2 
31.98 9.34 -0.139 1.101 
Claudin-1 β-Catenin 
siRNA-1 
31.78 8.91 -0.575 1.490 
Claudin-1 β-Catenin 
siRNA-2 
31.52 8.58 -0.904 1.871 
Claudin-1 RON 
siRNA-1 
31.71 8.71 -0.772 1.708 
Claudin-1 RON 
siRNA-2 
31.79 8.79 -0.693 1.617 
SnoN Control 
siRNA-1 
28.29 5.057 0 1 
SnoN Control 
siRNA-2 
28.25 4.952 -0.104 1.075 
SnoN SnoN 
siRNA-1 
29.42 6.648 1.591 0.332 
SnoN SnoN 
siRNA-2 
29.37 6.731 1.674 0.313 
SnoN β-Catenin 
siRNA-1 
28.16 5.282 0.226 0.855 
SnoN β-Catenin 
siRNA-2 
28.19 5.248 0.192 0.876 
SnoN RON 
siRNA-1 
28.20 5.195 0.138 0.909 
SnoN RON 
siRNA-2 
28.31 5.309 0.252 0.840 
RON Control 
siRNA-1 
33.93 10.70 0 1 
RON Control 
siRNA-2 
34.20 10.909 0.212 0.863 
RON SnoN 
siRNA-1 
34.02 11.242 0.544 0.686 
RON SnoN 
siRNA-2 
33.95 11.309 0.612 0.654 
RON β-Catenin 
siRNA-1 
34.69 11.816 1.119 0.461 
RON β-Catenin 
siRNA-2 
34.91 11.964 1.266 0.416 
RON RON 
siRNA-1 
34.82 11.818 1.121 0.459 
RON RON 
siRNA-2 
34.61 11.603 0.906 0.534 
 
Table 3.4 - Average and SD of Data.
Probe Sample Mean Standard 
Deviation 
Claudin-1 Control 
siRNA 
0.967 0.046 
Claudin-1 SnoN 
siRNA 
1.152 0.072 
Claudin-1 β-Catenin 
siRNA 
1.681 0.270 
Claudin-1 RON 
siRNA 
1.662 0.064 
SnoN Control 
siRNA 
1.038 0.053 
SnoN SnoN 
siRNA 
0.323 0.013 
SnoN β-Catenin 
siRNA 
0.865 0.014 
SnoN RON 
siRNA 
0.874 0.049 
RON Control 
siRNA 
0.932 0.097 
RON SnoN 
siRNA 
0.670 0.022 
RON β-Catenin 
siRNA 
0.438 0.032 
RON RON 
siRNA 
0.497 0.052 
Table 3.2- Averaged β-actin CT Values. 
Probe Sample Cт 
β-Actin 
Control siRNA-1 
23.23 
β-Actin 
Control siRNA-2 
23.29 
β-Actin 
SnoN siRNA-1 
22.78 
β-Actin 
SnoN siRNA-2 
22.63 
β-Actin 
β-Catenin siRNA-1 
22.88 
β-Actin 
β-Catenin siRNA-2 
22.95 
β-Actin 
RON siRNA-1 
23.00 
β-Actin RON siRNA-2 23.00 
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The PCR study yielded an Amplification Plot (Figure 3.10) from which CT (Threshold 
Cycle) values were obtained. Table 3.2 shows β-Actin CT values. We performed comparative 
qPCR analysis where we subtracted the CT value of β-actin from the CT value of claudin-1. This 
was similarly performed for the other genes of interest whose transcript levels were quantified. 
This resulted in a ΔCT value. ΔΔCT was calculated by normalizing samples to a reference 
sample. For example, Control-1 would be subtracted from SnoN-1 to obtain the ΔΔCT for SnoN. 
To determine the RNA-fold change, the following equation was used: 2-ΔΔCT. Sample 
calculations are shown in Table 3.3. Finally, the resulting values for each sample were averaged 
and standard deviations were derived (Tables 3.4).  
These data were then graphed (Figure 3.11). The knockdown of SnoN, β-catenin, and 
RON led to an increase in the abundance of claudin-1 mRNA transcripts (Figure 3.11a). 
However, this increase is observed most markedly with β-catenin and RON siRNA than SnoN 
siRNA. Additionally, β-catenin and RON knockdown resulted in a decrease in the abundance of 
SnoN mRNA transcripts (Figure 3.11b). Interestingly, SnoN and β-catenin knockdown resulted 
Figure 3.11 – Relative mRNA transcript levels of (A) claudin-1, (B) SnoN, and (C) RON resulting from SnoN, β-catenin, 
and RON siRNA transfection in HEY cells.  
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in a marked decrease in RON transcript levels (Figure 3.11c). Furthermore, the reduction is 
greater with β-catenin siRNA than with SnoN siRNA.  
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IV. Discussion  
 
Tight junction proteins such as claudin-1 are an integral component of epithelial junction 
complexes and play a vital role in maintaining epithelial integrity and cell polarity. Disruption of 
tight junctions is a hallmark of epithelial cancer development and malignant progression. The 
loss of claudin-1 expression has been shown to be correlated with increased invasiveness and 
malignant progression of certain epithelial cancers[14, 15]. Herein, we investigated whether 
claudin-1 expression is regulated by activation of mediators in the TGFβ signaling pathway, 
particularly SnoN/SkiL, a key TGFβ co-repressor, in ovarian cancer cells. This hypothesis was 
investigated through three specific aims: (1) to determine whether altered expression of RON 
tyrosine kinase leads to dysregulated claudin-1 expression; (2) to determine whether cellular 
treatment with TGFβ and MSP1 leads to altered expression levels of claudin-1; and (3) to 
determine whether knockdown of β-catenin and SnoN upregulates claudin-1 expression. 
In Figure 3.1 and 3.2, we observed that claudin-1 protein levels were increased with RON 
knockdown in HEY and SKOV3 cells, respectively. Similarly, as reported in breast cancer and 
MDCK cells, RON activation disrupts tight junctions and impairs their functions through 
reduced claudin-1 expression[17]. Interestingly, we also noted that β-catenin and SnoN levels 
were slightly increased in both SKOV3 and HEY cells. We propose that these changes may be 
independent of the effect of RON knockdown on claudin-1 levels since increased SnoN levels 
are expected to counter the effects of reduced RON expression.  However, we did not observe 
these effects in two independent cell lines, H358 and BxPC-3 cells, suggesting that these effects 
are likely unique to ovarian carcinoma cells.  
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In Figure 3.3, we investigated the immediate changes in the activation status of certain 
cascades following RON and TGFβRII/I receptor activation. We primarily focused on the MAP 
kinase signaling cascade since it is known to be a major player in numerous signaling pathways 
and modulates β-catenin activity[19-22]. Cells treated with MSP1 and TGFβ led to a marked 
phosphorylation of pERK1/2. We also noted that TGFβ is more potent in altering claudin-1 
levels in contrast to MSP1. In addition, long-term treatments (Figure 3.4 and 3.5) of these cells 
with these ligands led to marked reduction of claudin-1 levels. Thus, we propose that these 
changes in expression of these tight junction proteins may be due to the activation of the MAP 
kinase signaling cascade. We have observed an increase in SnoN levels and further, the inverse 
relationship between claudin-1 expression levels and SnoN supports the data presented in Figure 
3.9. Undeniably, disruption of tight junctions is indeed a hallmark of cancer development as 
noted in various cancer subtypes including colon cancer and as our work has potentially shown, 
in ovarian cancer development. 
We observed that siRNA targeting RON tyrosine kinase led to a marked elevation in 
claudin-1 protein. As shown in Figure 3.11, the changes that we observed in protein expression 
also occurred at the RNA level. This indicates that claudin-1 is regulated at the transcriptional 
level and since SnoN is a transcriptional co-repressor, this could be a potential pathway by which 
claudin-1 levels are modulated. The mechanism by which this could potentially occur is shown 
in Figure 4.1. Various mechanisms have been implicated in regulation of claudin-1 expression 
including regulators of the TGFβ and RON Tyrosine Kinase pathways. Studies with colon 
cancers have shown that Smad4, a co-Smad, involved in the TGFβ pathway represses claudin-1 
expression[18]. Activation of kinase linked receptors (i.e. RON and TGFβRII/I) normally occur 
following ligand binding (i.e MSP1 or TGFβ) followed by activation of intricate intracellular 
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signaling cascades (including MAP kinase activation, Figure 3.3) which leads to the progressive 
movement of the signal into the nuclear compartment. Within the nucleus, the activity of 
transcriptional co-repressors and co-activators modulate transcriptional induction. Both β-catenin 
and SnoN are mediators in such intracellular signaling pathways. 
One mechanism of β-catenin activation involves GSK3 (glycogen synthase kinase 3) 
which phosphorylates β-catenin and targets the protein for proteasome mediated degradation[19-
22]. Thus, dephosphorylated β-catenin will promote its cytoplasmic and thus, nuclear 
accumulation where it could potentially modulate the transcription of target genes such as 
claudin-1[19-22]. On the other hand, SnoN is regulated by phosphorylation via TAK1 which 
promotes its ubiquitination via E3 ubiquitin ligase and eventually determines the quantity of 
SnoN protein that is present[23]. Interestingly, we also noted that β-catenin and SnoN altered 
claudin-1 protein levels. These changes were observed at the RNA levels implicating 
transcriptional regulation of claudin-1. 
 With knockdown of SnoN and β-catenin, changes were observed in claudin-1 expression 
independent of the presence of ligand or receptor activation. With β-catenin knockdown, SnoN 
levels were reproducibly decreased suggesting that β-catenin may regulate SnoN expression 
either 1) directly via protein-protein interaction (via C-terminal binding protein which has been 
reported to interact in a complex with both SnoN and β-catenin) or 2) potentially indirectly via 
modulation of SnoN transcription as a β-catenin target gene. Strikingly, we noted that the 
morphology of the β-catenin knockdown HEY cells were more epithelial-like and polarized 
(results not shown). This observation is consistent with the role of claudin-1 in maintaining cell 
polarity in cell-cell interactions. This was not observed in RON or SnoN knockdown in cells; this 
indicates that there are some other critical components which aid or promote cell polarity such as 
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zonula occludens (ZO-1), gap junctions, and/or desmosomes. It is presently unknown whether 
the signaling mechanism by which β-catenin alters claudin-1 levels is through alteration in 
activities of SnoN transcription co-repressor activities. 
Future studies 
will investigate the 
effects of a MAP kinase 
inhibitor (PD98059) as 
well as other pathways 
including the PI3K/AKT, 
p38, and JNK pathways 
to further identify the 
signaling pathways 
leading to modulation of 
claudin-1 transcript 
levels. Thus, further 
elucidation of the 
detailed signaling events 
underlying regulation of 
claudin-1 expression will certainly be invaluable in future studies to identify novel biomarkers in 
ovarian cancer detection and treatment. 
 
 
 
RON and TGFβ Transcriptional regulation of Claudin-1 Expression
 
Figure 4.1-Proposed mechanism of claudin-1 regulation  via  SnoN  demonstrating potential 
cross-talk between the TGFβ signaling pathway and RON tyrosine kinase. 
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